Université de Montréal
Co-applicants: Dr. Claude Perreault, Dr. Pierre Thibault
Uncovering tumor specific antigens in ETP acute lymphoblastic leukemia
Early T-cell Precursor Acute lymphoblastic leukemia subtype (ETP-ALL) is associated with resistance to chemotherapy and poor prognosis, especially in adults. Stem cell transplantation is beneficial in a large proportion of patients which suggests high potential for immunotherapy for treatment of ETP-ALL. Our goal is to uncover tumor specific antigens (TSA), proteins on cancer cells. These proteins are present exclusively on leukemic cells and can be targeted for immunotherapy in ETP-ALL. This will pave the way to developing novel therapeutic vaccines for treatment of ETP-ALLs.